Primary and secondary autoimmune neutropenia by Capsoni, Franco et al.
208
AIN = autoimmune neutropenia; FasL = Fas ligand; FcγR = Fcγ receptor; G-CSF = granulocyte colony-stimulating factor; GIFT = granulocyte
immunofluorescence test; HNA = human neutrophil antigen; LGL = large granular lymphocyte; SLE = systemic lupus erythematosus.
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Abstract
Antineutrophil antibodies are well recognized causes of
neutropenia, producing both quantitative and qualitative defects in
neutrophils and increased risk for infection. In primary autoimmune
neutropenia (AIN) of infancy, a moderate to severe neutropenia is
the sole abnormality; it is rarely associated with serious infections
and exhibits a self-limited course. Chronic idiopathic neutropenia of
adults is characterized by occurrence in late childhood or
adulthood, greater prevalence among females than among males,
and rare spontaneous remission. Secondary AIN is more
commonly seen in adults and underlying causes include collagen
disorders, drugs, viruses and lymphoproliferative disorders. In most
patients with AIN, antibodies recognize antigens located on the
IgG Fc receptor type 3b but other target antigens have been
recently identified in secondary AIN. Granulocyte colony-
stimulating factor is a proven treatment in patients with AIN of all
types and is now preferred to other possible therapies.
Introduction
The term ‘neutropenia’ is used to define a condition in which
circulating neutrophils number less than 1500/µl. Neutro-
penias can be classified according to the mechanism of
induction, and so there are forms due to decreased
production of neutrophils, to sequestering of neutrophils from
endothelial or tissue pools, and to increased peripheral
destruction of neutrophils. It is perhaps more useful for
purposes of differential diagnosis to distinguish between
congenital and acquired forms, the latter being subdivided
according to their pathogenesis or aetiological agent
(Table 1).
Regardless of the cause, the clinical result of neutropenia is
always an increased infective diathesis, with frequency and
severity that are directly proportional to the degree of
neutropenia. This is considered mild when the neutrophil
count is between 1000 and 1500/µl, moderate when it is
between 500 and 1000/µl, and severe when it is less than
500/µl. Other factors may influence the severity of the
infective diathesis in a neutropenic patient: the speed of
onset and the duration of the neutropenia, the bone marrow
myeloid reserves, the absolute circulating monocyte count
and the functional status of phagocytes.
Immune mediated neutropenias (Table 1) involve a low neutro-
phil count resulting from increased peripheral destruction due
to antibodies directed against the cell membrane antigens.
The field of immune mediated neutropenias includes various
conditions such as alloimmune neutropenias (caused by
maternal–fetal incompatibility or transfusion reactions) and
true autoimmune forms. This review focuses on the true
autoimmune forms, which may be primary (i.e. not associated
with other pathologies) or secondary (usually to autoimmune
or haematological diseases).
Autoimmune neutropenias: pathogenesis and
diagnostic tests
The first convincing evidence that antineutrophil auto-
antibodies could cause neutropenia was presented in 1975,
when Boxer and coworkers [1] described five cases caused
by antineutrophil antibodies that facilitated phagocytosis of
opsonized neutrophils by splenic macrophages, and altered
some functional features of neutrophils. In the same year,
Lalezari and coworkers [2] showed that, to some extent,
autoantibodies could cause chronic neutropenia. Earlier
experiments conducted by Lawrence and coworkers [3] and
Simpson and Ross [4] had already demonstrated the
importance of antineutrophil autoantibodies in causing
neutropenia; those investigators showed that infusion into
guinea pigs of rabbit anti-guinea-pig neutrophil antibodies
caused neutropenia, as a result of phagocytosis of opsonized
neutrophils by splenic and bone marrow macrophages. In
humans autoantibodies also play a major opsonizing role –
possibly the main one – in inducing autoimmune neutropenia
(AIN) [1,5].
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The lack of close relation between the degree of neutropenia
and the levels of circulating autoantibodies [6] has been
attributed to various factors. The additional opsonizing activity
of complement, activated by antineutrophil autoantibodies,
may amplify phagocytosis [7]. Alternatively, the functional
status of the phagocytic system may render clearance of the
opsonized cells more or less effective [6]. Another important
point is that in some cases the capacity of autoantibodies to
induce neutropenia is related to their ability to recognize
antigenic determinants expressed not only by mature cells
but also by bone marrow myeloid precursors [8]. In such
cases the severe neutropenia is accompanied by bone
marrow hypoplasia, with maturational arrest and a significant
infective diathesis.
From the diagnostic point of view, the various methods for
detecting antineutrophil autoantibodies suffer from different
limitations and so they are not entirely comparable. These
limitations help to account for the different percentages of
patients positive for antineutrophil autoantibodies reported in
case series of AIN. No single method can identify all possible
antineutrophil autoantibodies [9,10]. The Second Inter-
national Granulocyte Serology Workshop [11] suggested
that a minimum of two methods be used to detect anti-
neutrophil autoantibodies: the granulocyte agglutination test
and the granulocyte immunofluorescence test (GIFT). The
granulocyte agglutination test is used to check whether a
serum sample sensitizes and therefore agglutinates control
neutrophils. The main limitation of this test is that neutrophils
tend to agglutinate spontaneously. The direct GIFT detects
autoantibodies bound to patient’s neutrophils, using
fluorescinated human anti-immunoglobulin antibodies. The
test suffers from the difficulty of obtaining enough cells from a
neutropenic patient; furthermore, considerable observer
experience is required to recognize the autofluorescence
typical of activated neutrophils, and because of the false-
positive results due to immune complexes bound to Fcγ
receptor (FcγR)II or FcγRIII and the possible presence of
antineutrophil alloantibodies.
For the indirect GIFT the patient’s serum is placed in contact
with control neutrophils, and autoantibodies are then
detected using a fluorescinated human anti-immunoglobulin
antiserum. This test also suffers from possible false-positive
findings due to immune complexes and antineutrophil
alloantibodies. These methodological difficulties can be
overcome by using the MAIGA (monoclonal antibody-specific
immobilization of granulocyte antigen) assay [12], which uses
specific monoclonal antibodies to capture neutrophil
membrane antigens that have bound human antibodies, thus
circumventing the interference from alloantibodies or immune
complexes. The assay, which is not routinely available, has
been used to identify antibodies against various human
neutrophil antigens (HNAs; see below).
However, whichever method is selected, it is often difficult to
detect antineutrophil autoantibodies because they are
present at low titres and bind to their targets with low avidity.
It is often necessary to repeat tests several times before it
may be concluded reliably whether antibodies are present.
Primary autoimmune neutropenia
The AINs are classified as primary (i.e. not associated with
other detectable pathology) or secondary, in cases in which
there is another pathology, usually rheumatological (particularly
Felty’s syndrome and systemic lupus erythematosus [SLE]) or
haematological (large granular lymphocyte [LGL] syndrome).
Primary autoimmune forms are the most frequent in new-
borns, with an incidence of 1/100,000 [9,10,13], and are
usually diagnosed during the first few months (5–15 months).
Although there is significant neutropenia at presentation
(500–1000 neutrophils/µl) the clinical course is usually
benign, with a moderate infective diathesis and a tendency to
Table 1
Classification of neutropenia
Type of 
neutropenia Neutropenias
Congenital Severe infantile agranulocytosis (Kostmann’s syndrome)
Shwachman–Diamond–Oski syndrome
Myelokathexis/neutropenia with tetraploid nuclei
Cyclic neutropenia
Chediak–Higashi syndrome
Reticular dysgenesis 
Dyskeratosis congenita
Acquired Postinfectious neutropenia
Drug-induced neutropenia
Complement activation (haemodialysis, leukapheresis, 
ARDS)
Immune neutropenia
Isoimmune neonatal neutropenia 
Alloimmune neutropenia (transfusion reaction)
Autoimmune neutropenia – primary
Benign of childhood
Adult chronic form
Autoimmune neutropenia – secondary
Autoimmune diseases
Large granular lymphocyte
Other (see Table 3)
Pure white cell aplasia
Chronic idiopathic neutropenia
Hypersplenism
Nutritional deficiency (vitamin B12 or folate deficiency)
Diseases affecting the bone marrow
Postchemotherapy
Aplastic anaemia
Fanconi anaemia
Myelodysplastic syndrome
Acute and chronic leukaemia
ARDS, acute respiratory distress syndrome.210
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resolve spontaneously by the age of 2 or 3 years in 95% of
cases. Severe infectious complications (pneumonia, sepsis,
meningitis) are seen in about 12% of the patients.
In these forms of AIN the bone marrow is typically normo-
cellular or hypercellular, with a normal or low number of
mature neutrophils. The response of bone marrow to infection
is usually preserved, explaining the moderate infective
diathesis. There is often peripheral monocytosis. In the few
cases with a more severe clinical course there may be
maturation arrest in the myelocyte/metamyelocyte stage or
bone marrow hypocellularity, probably because the
autoantibodies recognize antigens expressed not only by
mature neutrophils but also by their bone marrow precursors.
The autoantibodies responsible for primary AIN act against
HNAs, which are defined and classified in Table 2, in accor-
dance with the findings of the International Granulocyte
Antigen Working Party [14]. In most cases these antigens are
glycosylated isoforms of FcγRIIIb (or CD16b), which are linked
to the plasma membrane via a glycosylphosphatidylinositol
anchor and are selectively expressed by neutrophils [15].
Bux and coworkers [13] reported that 35% of their patients
with primary AIN had anti-HNA-1a and anti-HNA-1b auto-
antibodies. Bruin and coworkers [16] found that about 80%
of their neutropenic patients were positive for these auto-
antibodies. Less frequently the antineutrophil autoantibodies
recognize adhesion glycoproteins of the CD11/CD18
(HNA-4a, HNA-4b) complex [17], the CD35 molecule (CR1)
and FcγRIIb (for review, see Maheshwari and coworkers [9]).
We do not know the origin of these autoantibodies. However,
like other autoimmune responses, it might involve molecular
mimicry of microbial antigens, modification of endogenous
antigens as a result of drug exposure, increased or otherwise
abnormal expression of HLA antigens, or loss of suppressor
activity against self-reactive lymphocyte clones.
In the presence of antineutrophil autoantibodies, the infective
diathesis is not solely due to the severity of the neutropenias;
these antibodies can influence various phagocyte functions,
sometimes without causing substantial neutropenia [10,18].
Defects of adhesion, aggregation, chemotaxis, phagocytosis
and metabolic activation have been reported in patients with
AIN, and antineutrophil autoantibodies induced similar defects
in control neutrophils. The clinical significance of these
functional alterations is not clear but they may explain the
infective diathesis seen in some patients with antineutrophil
autoantibodies but no significant neutropenia.
Chronic idiopathic neutropenia in the adult differs from the
neonatal autoimmune form in that, by definition, it appears
much later in life; the incidence is higher among females
(70% of cases); it exhibits little tendency toward spon-
taneous remission (although it remains clinically benign); it
may be associated with anaemia and thrombocytopenia
(40%); and only 35% of cases are positive for antineutrophil
autoantibodies [10,19].
The primary AINs are usually benign or at any rate self-
limiting. Most cases therefore require no specific therapy.
Antibiotics are normally sufficient to deal with infections. The
utility of medium-term to long-term antibiotic prophylaxis,
usually with cotrimoxazole [10,13], must be assessed on a
case by case basis.
In patients with severe infections or in those who require
surgical intervention, remission can be achieved by treatment
with corticosteroids, intravenous IgG and growth factors,
particularly granulocyte colony-stimulating factor (G-CSF)
[9,10,13]. Steroids, used in small case series in the past,
appear to have limited effect on immune-mediated
neutropenias, although there are reports of activity in primary
and secondary autoimmune forms [13]. They seem to work by
blocking the reticuloendothelial system and by reducing the
formation of autoantibodies. However, their multiple side
Table 2
Human neutrophil antigen nomenclature
Caucasian phenotype 
Antigen system Antigen Glycoprotein Acronym frequency (%)
HNA-1 HNA-1a FcγRIIIb NA1 58
HNA-1b FcγRIIIb NA2 88
HNA-1c FcγRIIIb SH 5
HNA-2 HNA-2a gp50-64 NB1 97
HNA-3 HNA-3a gp70-95 5b 97
HNA-4 HNA-4a CD11b MART 99
HNA-5 HNA-5a CD11a OND 96
Based on Bux [14]. FcγR, Fcγ receptor; HNA, human neutrophil antigen.211
effects, particularly the increased incidence of infection, have
limited their use in this pathology.
Treatment with intravenous IgG is potentially useful in AIN
because it transiently inhibits the reticuloendothelial system.
However, such treatments are not always active (50% of cases)
and, importantly, the effect is short lasting (1–2 weeks) [13].
For primary forms of AIN, G-CSF is currently the first-line
therapy to achieve remission of the neutropenia (for review,
see Smith and Smith [20]). The goal is to keep the neutrophil
count above 1000/µl, which can usually be done by giving
G-CSF intravenously or subcutaneously at a dose of
5–10 µg/kg per day for 3 days, after which further doses can
be given, depending on the response. The biological effect of
G-CSF is not merely to stimulate proliferation and maturation
of neutrophil progenitors or to release mature cells into the
bloodstream. This factor also stimulates phagocyte function;
reduces neutrophil apoptosis; reduces neutrophil membrane
antigen expression, thus making the autoantibodies less
active; and raises levels of soluble FcγRIIIb, sequestering
autoantibodies [20]. The long-term adverse effects of G-CSF
(reduction in myeloid precursors, formation of anti-G-CSF
antibodies, osteopenia; for review, see Maheshwari and
coworkers [9]) do not normally affect patients with primary
AIN, which is usually benign and self-limited, but they must be
borne in mind in more severe forms of immune-mediated
neutropenia, which require lengthy treatment. The use of G-
CSF in AIN is justified in cases of severe infection or in those
who are scheduled for surgery.
Other therapeutic approaches for patients with severe
neutropenia that is not responding to conventional therapies
have been reported in very small series or even single
patients; they include plasmapheresis, splenectomy and
cytotoxic drugs [10]. Sustained remission of severe resistant
AIN has been achieved with Campath-1H, a humanized
monoclonal antibody that recognizes the nonmodulating
panlymphocyte antigen CD52 and induces cellular lysis in the
presence of complement [21,22].
Secondary autoimmune neutropenia
Although AIN is most likely to be secondary to systemic
autoimmune diseases [23-27], it is also seen in other clinical
situations. Examples are infectious diseases [28-30], solid or
haematological neoplasms [31,32], neurological diseases [33],
bone marrow or stem cell transplants [34,35], kidney
transplants [36,37], and use of certain drugs [38-40] (Table 3).
Secondary forms of AIN have some distinguishing features.
First, in secondary AIN antineutrophil antibodies are usually
only one of the causes of the neutropenia, which may be
associated (depending on the case) with peripheral
sequestration, bone marrow inhibition, or apoptosis (see
below). Second, in most cases of secondary AIN the target of
the autoantibodies is unknown. Third, these cases quite
commonly also present with thrombocytopenia and/or
haemolytic anaemia, and they may also have functional
defects of phagocytes in the absence of neutropenia [41-43].
Finally, in most of these situations therapy for the cytopenia is
the same as – or at least includes – treatment for the
underlying disease.
The systemic autoimmune diseases most often seen together
with AIN include rheumatoid arthritis (i.e. Felty’s syndrome)
and SLE. There is also a complex haematological condition
known as ‘large granular lymphocyte’ (LGL) syndrome, which
closely resembles Felty’s syndrome clinically. The fact that
AIN is frequently seen with these pathologies has led to a
better pathogenic definition of the cytopenia.
Felty’s syndrome is a rare but severe form of seropositive
rheumatoid arthritis, which is usually long-lasting and
associated with neutropenia and, although not necessarily,
splenomegaly. The neutropenia in these patients has a
complex, multifactorial pathogenesis. There is destruction and
peripheral margination by the antineutrophil autoantibodies
and by immune complexes adhering to these cells [27], but
the severe neutropenia is also partly due to inhibition of bone
marrow granulopoiesis by proinflammatory cytokines (inter-
leukin-1, tumour necrosis factor-α, interferon-γ) [44]. The
resulting neutropenia is frequently severe (<0.2 × 109/l) and,
together with functional alterations to circulating cells, leads
to an equally severe infective diathesis, often with poor
prognosis.
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Table 3
Secondary autoimmune neutropenias 
Type of disorder Disease Ref.
Systemic autoimmune diseases PBC [23]
Sjögren’s syndrome [24]
SS [25]
SLE [26]
RA [27]
Infectious diseases Helicobacter pylori [28]
HIV [29]
Parvovirus B19 [30]
Tumor Wilms tumor [31]
Hodgkin’s disease [32]
Neurological diseases MS [33]
Transplantation Stem cell [34]
BMT [35]
Kidney [36,37]
Drugs Fludarabine [38]
Propylthiouracil [39]
Rituximab [40]
BMT, bone marrow transplantation; MS, multiple sclerosis; PBC,
primary biliary cirrhosis; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; SS, systemic sclerosis.212
In Felty’s syndrome recent studies have started to clarify the
antigenic specificity of the antineutrophil autoantibodies. In
most of these patients, in fact, the target antigens of auto-
antibodies were the eukaryotic elongation factor 1A-1 antigens.
This molecule, which is needed for peptide synthesis, can – in
vitro  at least – be translocated from the nucleus to the
membrane during apoptosis, suggesting how the auto-
antibodies could bind to the cell surface of neutrophils [45].
As we mentioned above, therapy for neutropenia in Felty’s
syndrome is often the same as the patient needs for the
underlying pathology, usually methotrexate [46], cyclosporine A
[47], leflunomide [48] and parenteral gold [49]. Cortico-
steroids have shown some transient activity in neutropenia
but their side effects are a contraindication in these patients,
except for special cases. Splenectomy for patients not
responsive to other therapies has shown some utility but
there is a higher incidence of postoperative sepsis [50,51].
As things stand at present, the therapeutic approach to
infectious complications in Felty’s syndrome involves
continuing the basic therapy and adding a growth factor,
specifically G-CSF, to achieve prompt recovery of the
circulating neutrophil count and better control of infection [52].
Nevertheless, the larger supply of circulating activated
leukocytes raises the risk of arthritic flare-ups and/or leuko-
cytoclastic vasculitis in these patients [53]. These complica-
tions can at least partially be prevented by using low doses of
G-CSF (3 µg/kg per day) [52] with medium or low doses of
corticosteroids (0.3–0.5 mg/kg per day prednisone equivalent).
Another potential problem is that there are no reliable
indications regarding the duration of G-CSF treatment in
Felty’s syndrome. Often, once the infection has been
resolved, good control of the basic disease with the usual
drugs is sufficient to keep neutropenia within safe limits. If
severe neutropenia persists (<0.2 × 109/l) then G-CSF could
be continued at the lowest effective dose (to maintain
circulating neutrophils >1000/µl).
Some patients with Felty’s syndrome have not only
neutropenia but also an elevated number of circulating and
bone marrow LGLs – a heterogeneous population of cells
that includes natural killer cells and activated cytotoxic T cells
[54]. The expansion of these LGLs may be reactive, but more
often it is clonal, giving rise to LGL leukaemia [55].
Independently of whether the patient also has joint
symptoms, LGL leukaemia is almost inevitably associated
with neutropenia of multifactorial origin [56]: inhibition of
myelopoiesis by cytokines produced locally by the LGL cells,
and antineutrophil autoantibodies. There seems, however, to
be a third pathogenic mechanism as well. The cells of
patients with LGL leukaemia, unlike LGL cells in healthy
individuals, constitutively express Fas ligand (FasL) in the
membrane [57] and their serum contains high levels of
soluble FasL [58], probably resulting from ‘shedding’ of the
molecule by metalloproteinases.
In patients with Felty’s syndrome and LGL expansion, the
neutropenia might be due to apoptosis resulting from the
binding of soluble FasL to Fas bearing neutrophils [59]. This
is borne out by the observation that when neutropenia
improves with methotrexate treatment, FasL always drops or
even disappears from serum [59]. Methotrexate and cyclo-
sporine A inhibit FasL secretion by LGLs, reducing the amount
of apoptosis, and both drugs have proved effective for con-
trolling LGL leukaemia and its associated neutropenia [60,61].
Although neutropenia is fairly common in SLE patients (47%
in the case list reported by Nossent and Swaak [62]), the
autoimmune forms are extremely rare, certainly less common
than other autoimmune cytopenias (haemolytic anaemia and
thrombocytopenia). SLE patients frequently have anti-
neutrophil autoantibodies in their serum or adhering to
circulating neutrophils (50–70%) [6,63], but they do not
always have neutropenia. One possible reason might lie in the
functional defect in the phagocytic system in SLE, which
allows opsonized cells to remain longer in circulation [6,41].
The antineutrophil autoantibodies in SLE usually exhibit anti-
FcγRIIIb specificity [16], although there are now reports of a
correlation between neutropenia and anti-Ro/SSA auto-
antibodies. These appear to recognize a 64 kDa neutrophil
membrane molecule that is antigenically similar to Ro/SSA; in
this way, anti-Ro/SSA autoantibodies could opsonize neutro-
phils and fix complement [64]. Another autoimmune compo-
nent in the pathogenesis of neutropenia – actually of cyto-
penia – in SLE might be antibodies against CD34+ haemato-
poietic progenitors, which significantly inhibit haematopoiesis
in toto [65].
Finally, the reportedly high number of apoptotic circulating
neutrophils in SLE patients might be another cause of
neutropenia and a possible indicator of active disease [66].
Therapy for AIN in SLE also starts with good control of the
underlying disease. G-CSF was used in nine patients with
severe refractory neutropenia and infectious complications
[67]. There was prompt recovery of the circulating neutro-
phils and the infection responded well, but in one-third of
these patients the disease flared up and there was one case
of leukocytoclastic vasculitis.
Like in Felty’s syndrome, in patients with SLE and neutro-
penia G-CSF should preferably only be used in selected
cases, at the lowest dose that achieves a circulating neutro-
phil count of at least 1000/µl [52].
Conclusion
AINs are rare disorders in which autoantibodies directed
against membrane antigens of neutrophils causes their
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peripheral destruction. In primary forms of AIN autoantibody
specificity has been defined, and usually autoantibodies
recognize antigens located on the FcγRIIIb. In secondary
forms of AIN autoantibody specificity is often unknown,
although possible target antigens of neutrophils were recently
identified in patients with Felty’s syndrome or with SLE. The
diagnosis of AIN is based on evidence of antineutrophil anti-
bodies. Because of the difficulties associated with detection
of neutrophil autoantibodies, a combination of immuno-
fluorescence and agglutination tests has proven to be the
best antibody screening procedure. G-CSF is at present the
first-line therapy for primary AIN to achieve remission of
neutropenia. Severe or unresponsive secondary AIN may be
treated with G-CSF to increase neutrophil counts and reduce
the risk for infection. However, in patients with Felty’s syndrome
or SLE, the potential for flare-up of rheumatic disease means
that judicious use of the growth factor is required.
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